 |
Justin Petrone is the editor of GenomeWeb's BioArray News and covers the microarray and biochip sector of the genomics market. E-mail Justin Petrone or follow his GenomeWeb Twitter account at @BioArrayNews. |
CombiMatrix Sees Focus on CMA Pay off as it Reports 172 Percent Q4 Prenatal Testing Growth
January 08, 2013
CombiMatrix Sees Focus on CMA Pay off as it Reports 172 Percent Q4 Prenatal Testing Growth
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CombiMatrix Bets on Array-Based Prenatal Testing, Affy Clinical Trials Deal to Drive Growth in H2
August 14, 2012 / BioArray News - NEJM Papers Support Use of Arrays in Prenatal Dx as Sequencing Gains Ground
December 11, 2012 / BioArray News - Israeli Health Ministry to Subsidize Chromosomal Microarray Analysis for High-risk Pregnancies
May 8, 2012 / BioArray News - Study Finds Array-based Prenatal Testing More Informative than Standard Karyotyping
February 14, 2012 / BioArray News - CombiMatrix to Introduce Gene-Mutation Testing; Q2 Revenues Climb 31 Percent
August 16, 2011 / BioArray News